Use of Anti Angiogenic Drug in the Treatment for Age Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness. Currently 2.5-3 million people worldwide are blind due to AMD.
Objective:- This study were to use of anti-angiogenic drug in the treatment for age related macular degeneration.
Methods: A cross sectional study was carried out among patients attending Eye OPD of a tertiary care eye center.
Results: 25 patients were included in this study . Among the 25 patients 15 were male & 10 were female. Mean visual acuity (VA) in this study improved from 5/60 to 6/36 during follow up. This was statistically significant (P <0.0001).
Conclusion: The results of this study suggest that IVB (1.25 mg) is well tolerated and associated with stabilization or improvement in visual acuity, decreased central macular thickness (CMT) by ocular coherence tomography (OCT), and reduction in angiographic leakage associated with neovascular AMD.
2. Magnitude and causes of visual impairment WHO 04.138
3. Global causes of blindness as a proportion of total blindness in 2002
4. Statistics on Blindness and Blinding Diseases in the United States. 1997-2004 University of Washington Department of Ophthalmology
5. Thylefors B. A global initiative for the elimination of avoidable blindness. Am J Ophthalmol 1998; 125: 90-93
6. Nirmalan PK, Katz J, Robin AL, et al. Prevalence of vitreo retinal disorders in a rural population of Southern India: The Aravind Comprehensive Eye Study. Arch Ophthalmol. 2004; 122:581–586.
7. Sanjeev K. Gupta, Gudlavalleti V. S. Murthy, Nicoli Morrison, Gill M. Price, Mukesh Dherani, John,Astrid E. Fletcher, and Usha Chakravarthy Prevalence of Early and Late Age-Related Macular Degeneration in a Rural Population in Northern India: The INDEYE Feasibility Study Investigative Ophthalmology and Visual Science. 2007; 48:1007-1011.
8. Krishnaiah S, Das TP, Nirmalan PK, et al. Risk factors for age-related macular degeneration: findings from the Andhra Pradesh Eye Disease Study in south India. Invest Ophthalmol Vis Sci. 2005; 46:4442–4449.
9. Rajan SI, Sarma PS, Mishra US. Demography of Indian aging, 2001–2051. J Aging Soc Policy. 2003;15:11–30
10. Brody BL, Gamst AC, William RA, et al. Depression, visual axis, comorbidity and disability associated with age related macular degeneration. Ophthalmology 2001; 108: 1893-1900.
11. Lim, Jennifer, Kwok Alvin, K. Wilson, Deanna. Symptomatic age-related macular degeneration in Asian patients. Retina;1998 - 18 -5: 399-465.
12. Ferris FL III. Senile macular degeneration. Review of epidemiologic features. Am J Epidemiol 1983; 118: 132-5.
13. Z. Bashshur, Z. Haddad, A. Schakal, R. Jaafar, A. Saad, B. Noureddin Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study American Journal of Ophthalmology;148-1: 59-65
14. R.Lucas, H. McKee, L Lee Intravitreal Bevacizumab. Ophthalmology;114-2:400
15. 76. Nguyen QD, for the CLEAR-IT 1 Investigators. A randomized comparison of the safety, tolerability, and bioactivity study of two dose levels of intravitreal VEGF trap in patients with neovascular age-related macular degeneration. Presented at the Retina SocietyAnnual Scientific Meeting. Sept. 27-30, 2007. Boston